RPG Life Sciences, through its wholly owned subsidiary RPG Active Pharma Ltd, agrees to acquire the active pharmaceutical ingredients (API) and intermediates business of Raghava Life Sciences in a transaction valued at up to ₹135 crore. Business Line frames the deal as part of RPG Active Pharma’s consolidation and buy-and-build approach to create an API-focused organization.
Free Press Journal adds further details, saying the acquisition is completed as a going concern through a slump sale, subject to customary closing conditions and regulatory approvals. The outlet also states the portfolio will add 22 commercialised APIs and seven development-stage assets, spanning areas including diabetes, cardiovascular and central nervous system disorders. It describes the deal as RPG Active Pharma’s second strategic acquisition after Actis Generics, aimed at expanding integrated API capabilities and manufacturing footprint.
While both sources identify the same buyer, target, price and strategic intent, they differ mainly in emphasis: Business Line highlights consolidation and the broader buy-and-build strategy, while Free Press Journal provides more operational specifics about the assets being acquired, deal structure, financing and advisers.
